Trial | NCT04388202  Report issue

Title

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (LEAP-SE): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Sertraline Versus Escitalopram in Adults With Major Depressive Disorder

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
The LEAP-SE study is an 8-week, multicenter, randomized, blinded study to evaluate the performance of EEG-based biomarkers in predicting treatment outcome. Study participants will be randomized in a 1:1 ratio to receive either sertraline or escitalopram and followed for 8 weeks.
Study Started
Oct 15
2020
Anticipated
Primary Completion
May 30
2023
Anticipated
Study Completion
May 30
2023
Anticipated
Last Update
Oct 19
2020

Drug Sertraline

FDA approved antidepressant

  • Other names: Zoloft

Drug Escitalopram

FDA approved antidepressant

  • Other names: Lexapro

Sertraline Experimental

Sertraline 100-200 mg daily for 8 weeks

Escitalopram Active Comparator

Escitalopram 10-20 mg daily for 8 weeks

Criteria 

Inclusion Criteria:

Male or female, aged 22 or older at the time of informed consent.
Diagnosis of Major Depressive Disorder (MDD) based on the Structured Clinical Interview for DSM-5 for depression.
Moderate or severe depression on DSM-5 depression criteria items, as assessed by a score of 10 or more on the Patient Health Questionnaire (PHQ-9)
Has not taken either study medications (sertraline, escitalopram) in the current episode
Has not received electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or esketamine treatment in the current episode
Provision of personally signed and dated written informed consent prior to any study procedures
Agrees to, and is eligible for all biomarker assessments (EEG, neurocognitive testing, activity and sleep monitoring, genetic testing)
Fluent in English
Ability to complete all assessments independently
Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

Diagnosis of bipolar disorder or a psychotic disorder based on the Structured Clinical Interview for DSM-5.
Concurrent use of antidepressants, antipsychotics or mood stabilizers
Use of hypnotics, anxiolytics or opiate pain medications greater than three days per week and unable to reduce use to three or fewer days per week on an as needed basis
Pregnant or breastfeeding
Severe impediment to vision, hearing, comprehension, and/or hand movement that interferes with study tasks
Active substance use that interferes with ability to consent and/or complete assessments
Any contraindication to EEG (e.g. requiring high concentration oxygen)
Employees/family of employees of clinic site
Participation in another research study within 2 months prior to the first study visit
No Results Posted